Axinn represented the URL/Mutual Pharmaceutical Companies in connection with the launch of various products containing the active ingredient guaifenesin. This representation included the defense of Hatch-Waxman patent litigation filed by Adams Respiratory Therapeutics, Inc. in both New Jersey and Pennsylvania in October 2006. Axinn successfully opposed Adams’ efforts to stay the Pennsylvania proceedings, and trial is currently scheduled for April 2007. In addition, Axinn filed antitrust and other counterclaims against Adams, alleging that Adams filed these baseless actions for the purpose of delaying FDA approval of its client’s guaifenesin products.
Axinn Represents URL/Mutual Companies in Launch of Guaifenesin Products
October 30, 2006